140 related articles for article (PubMed ID: 28978958)
1. Vedolizumab in Patients With Common Variable Immune Deficiency and Gut Inflammation.
Boland BS; Riedl MA; Valasek MA; Crowe SE; Sandborn WJ
Am J Gastroenterol; 2017 Oct; 112(10):1621. PubMed ID: 28978958
[No Abstract] [Full Text] [Related]
2. Vedolizumab Induced Clinical, Endoscopic, and Histological Improvement in Common Variable Immunodeficiency Disease-associated Intestinal Enteropathy.
Akhtar HJ; Markandey B; Ma C; Ramsewak D; Walsh JC; Jairath V
Inflamm Bowel Dis; 2020 Mar; 26(4):e22-e23. PubMed ID: 32002555
[No Abstract] [Full Text] [Related]
3. Vedolizumab therapy in common variable immune deficiency associated enteropathy: A case series.
Sifers T; Hirten R; Mehandru S; Ko HM; Colombel JF; Cunningham-Rundles C
Clin Immunol; 2020 Mar; 212():108362. PubMed ID: 32058070
[TBL] [Abstract][Full Text] [Related]
4. Infliximab as treatment of severe enteropathy in a patient with common variable immunodeficiency and cytomegalovirus infection.
Prieto Elordui J; Arreba Gonzalez P; Ortiz de Zarate Sagastagoitia J; Deiss Pascual L; Blanco Sampascual S; Baranda Martín A; Calderón García A; Muñoz Villafranca C
Gastroenterol Hepatol; 2018 Mar; 41(3):163-164. PubMed ID: 28476306
[No Abstract] [Full Text] [Related]
5. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.
Fleisher M; Marsal J; Lee SD; Frado LE; Parian A; Korelitz BI; Feagan BG
Dig Dis Sci; 2018 Apr; 63(4):825-833. PubMed ID: 29484571
[TBL] [Abstract][Full Text] [Related]
6. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.
Bergqvist V; Hertervig E; Gedeon P; Kopljar M; Griph H; Kinhult S; Carneiro A; Marsal J
Cancer Immunol Immunother; 2017 May; 66(5):581-592. PubMed ID: 28204866
[TBL] [Abstract][Full Text] [Related]
7. Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects.
Pijls PA; Gilissen LP
Dig Liver Dis; 2016 Nov; 48(11):1391-1393. PubMed ID: 27639825
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab for intestinal amyloidosis complicated by multi-centric Castleman's disease.
Tamura T; Tamura S; Tanaka H; Ohagi Y; Taniguchi F; Yamanishi H; Kohara T; Kimura R; Kurihara T; Ozaki T; Nakano Y; Fujimoto T
Clin Res Hepatol Gastroenterol; 2015 Dec; 39(6):e79-81. PubMed ID: 26072317
[No Abstract] [Full Text] [Related]
9. Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-α drug failure.
Sáez-González E; Aguas M; Huguet JM; Nos P; Beltrán B
Dig Liver Dis; 2018 Apr; 50(4):415-417. PubMed ID: 29397323
[No Abstract] [Full Text] [Related]
10. Vedolizumab Concentrations in the Breast Milk of Nursing Mothers With Inflammatory Bowel Disease.
Julsgaard M; Kjeldsen J; Bibby BM; Brock B; Baumgart DC
Gastroenterology; 2018 Feb; 154(3):752-754.e1. PubMed ID: 28988916
[No Abstract] [Full Text] [Related]
11. Vedolizumab Is Safe and Effective in Elderly Patients with Inflammatory Bowel Disease.
Navaneethan U; Edminister T; Zhu X; Kommaraju K; Glover S
Inflamm Bowel Dis; 2017 Apr; 23(4):E17. PubMed ID: 28296827
[No Abstract] [Full Text] [Related]
12. Vedolizumab for treatment of steroid-refractory lower gastrointestinal acute graft-versus-host disease.
Coltoff A; Lancman G; Kim S; Steinberg A
Bone Marrow Transplant; 2018 Jul; 53(7):900-904. PubMed ID: 29371686
[No Abstract] [Full Text] [Related]
13. Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation.
Wright AP; Fontana RJ; Stidham RW
Liver Transpl; 2017 Jul; 23(7):968-971. PubMed ID: 28296011
[No Abstract] [Full Text] [Related]
14. Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis.
Navarini AA; Hruz P; Berger CT; Hou TZ; Schwab C; Gabrysch A; Higgins R; Frede N; Padberg Sgier BC; Kämpe O; Burgener AV; Marquardsen F; Baldin F; Bigler M; Kistner A; Jauch A; Bignucolo O; Meyer B; Meienberg F; Mehling M; Jeker LT; Heijnen I; Daikeler TD; Gebbers JO; Grimbacher B; Sansom DM; Jeker R; Hess C; Recher M
J Allergy Clin Immunol; 2017 Mar; 139(3):1043-1046.e5. PubMed ID: 27908448
[No Abstract] [Full Text] [Related]
15. Letter to editor: New onset/recurrence of inflammatory arthralgia/spondyloarthritis in patients treated with vedolizumab for intestinal bowel disease.
Tamanini S; Fredi M; Crisafulli F; Lazzaroni MG; Tincani A; Franceschini F
Clin Rheumatol; 2019 Feb; 38(2):609-610. PubMed ID: 30397839
[No Abstract] [Full Text] [Related]
16. Vedolizumab for Crohn's disease.
Mosli MH; Feagan BG
Expert Opin Biol Ther; 2013 Mar; 13(3):455-63. PubMed ID: 23394379
[TBL] [Abstract][Full Text] [Related]
17. The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases.
Macaluso FS; Orlando R; Fries W; Scolaro M; Magnano A; Pluchino D; Cappello M; Morreale GC; Siringo S; Privitera AC; Ferracane C; Belluardo N; Alberghina N; Ventimiglia M; Rizzuto G; Renna S; Cottone M; Orlando A
Dig Liver Dis; 2018 Jul; 50(7):675-681. PubMed ID: 29576495
[TBL] [Abstract][Full Text] [Related]
18. Systemic Chemokine Levels with "Gut-Specific" Vedolizumab in Patients with Inflammatory Bowel Disease-A Pilot Study.
Zwicker S; Lira-Junior R; Höög C; Almer S; Boström EA
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829369
[TBL] [Abstract][Full Text] [Related]
19. Vedolizumab as a Novel Treatment for Refractory Collagenous Colitis: A Case Report.
Cushing KC; Mino-Kenudson M; Garber J; Lochhead P; Khalili H
Am J Gastroenterol; 2018 Apr; 113(4):632-633. PubMed ID: 29610507
[No Abstract] [Full Text] [Related]
20. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
Zeissig S; Rosati E; Dowds CM; Aden K; Bethge J; Schulte B; Pan WH; Mishra N; Zuhayra M; Marx M; Paulsen M; Strigli A; Conrad C; Schuldt D; Sinha A; Ebsen H; Kornell SC; Nikolaus S; Arlt A; Kabelitz D; Ellrichmann M; Lützen U; Rosenstiel PC; Franke A; Schreiber S
Gut; 2019 Jan; 68(1):25-39. PubMed ID: 29730603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
